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ABSTRACT
Renal cell cancer (RCC) is characterized by histological and molecular 
heterogeneity that may account for variable response to targeted therapies. We 
evaluated retrospectively with a next generation sequencing (NGS) approach using 
a pre-designed cancer panel the mutation burden of 32 lesions from 22 metastatic 
RCC patients treated with at least one tyrosine kinase or mTOR inhibitor. We identified 
mutations in the VHL, PTEN, JAK3, MET, ERBB4, APC, CDKN2A, FGFR3, EGFR, RB1, 
TP53 genes. Somatic alterations were correlated with response to therapy. Most 
mutations hit VHL1 (31,8%) followed by PTEN (13,6%), JAK3, FGFR and TP53 (9% 
each). Eight (36%) patients were wild-type at least for the genes included in the 
panel. 
A genotype concordance between primary RCC and its secondary lesion was 
found in 3/6 cases. Patients were treated with Sorafenib, Sunitinib and Temsirolimus 
with partial responses in 4 (18,2%) and disease stabilization in 7 (31,8%). Among the 
4 partial responders, 1 (25%) was wild-type and 3 (75%) harbored different VHL1 
variants. Among the 7 patients with disease stabilization 2 (29%) were wild-type, 2 
(29%) PTEN mutated, and single patients (14% each) displayed mutations in VHL1, 
JAK3 and APC/CDKN2A. Among the 11 non-responders 7 (64%) were wild-type, 2 
(18%) were p53 mutated and 2 (18%) VHL1 mutated. 
No significant associations were found among RCC histotype, mutation variants 
and response to therapies. In the absence of predictive biomarkers for metastatic 
RCC treatment, a NGS approach may address single patients to basket clinical trials 
according to actionable molecular specific alterations.
INTRODUCTION
Renal cell carcinoma (RCC) accounts for the 2-3% 
of all adult malignancies, the seventh most common cancer 
in men and the ninth in women. [1] Localized RCC can be 
successfully cured by surgery in most cases. Unfortunately, 
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about 30% of patients relapse after nephrectomy or present 
at diagnosis with metastatic disease (mRCC)[2]. Despite 
the therapeutic improvements made in the past decade, 
mRCC is still an incurable disease. [3]
Several studies outlined that the multiple histological 
features of RCC corresponded to a molecular intra- and 
inter-tumoral heterogeneity with prognostic and predictive 
implications.[3, 4, 5, 6, 7] The improved knowledge of the 
biology and pathogenesis of RCC, lead to major treatment 
advances through the development of targeted agents. [2] 
The currently available therapeutic options for mRCC 
include drugs targeting circulating vascular endothelial 
growth factor (VEGF) and its receptors (VEGFRs), other 
tyrosine kinase inhibitors (TKIs) and inhibitors of the 
mammalian target of rapamycin (mTOR) serine-threonine 
kinase [2]. Unfortunately, 20 to 30% of mRCC patients do 
not respond at all to targeted agents while the remaining 
ultimately progress after an initial benefit. [8] There is 
current need for molecular biomarkers of RCC for the 
development of a personalized treatment and predictive 
approach for patient stratification. [8] According to the 
Cancer Genome Atlas database the most frequent somatic 
mutations in ccRCC include mainly alterations of the 
VHL gene and its partners involved in neo-angiogenesis 
and response to hypoxia, followed by alterations of the 
PI(3)K/AKT/mTOR pathway. [9] Conversely, the most 
frequent somatic genetic changes in non-ccRCC such as 
the papillary histotype (pRCC) involve mutations or copy 
number variations of the MET oncogene or loss of the 
tumor suppressor gene CDKN2A. [3, 10] 
Unfortunately, no correlation was found so far 
among biomarker expression/alteration and clinical 
response to single TKIs and mTOR inhibitors. In addition, 
there is no clear-cut evidence that the ccRCC or the non-
ccRCC histotypes respond differently to specific target 
therapies [9, 11]
In this study, we have evaluated retrospectively 
with a next generation sequencing (NGS) approach the 
mutation burden of 32 primary and/or secondary lesions 
of 22 patients with mRCC treated with at least one TKI 
or mTOR inhibitor. We then associated the presence of 
every identified somatic tumor alteration with response to 
therapy.
Patients’ selection criteria
We have retrospectively analyzed 32 RCC nodules/
metastases from 22 patients with mRCC enrolled and 
surgically resected at the S.Orsola-Malpighi Hospital 
(Bologna) and the Policlinico GB Rossi Hospital (Verona) 
from 2001 to 2013. Informed consent for genetic analyses 
was obtained from the patients before surgery.
Selection criteria for patients’ enrolment were: 1) 
presence of mRCC at the time of surgery or development 
of metastases thereafter; 2) Availability of at least one 
formalin-fixed paraffin-embedded (FFPE) surgical 
pathology cancer specimen; 3) Systemic treatment with 
at least one of the anticancer agents registered in Italy 
for mRCC; 4) availability of at least 6 month follow-up 
from the beginning of the first line of treatment. When 
available, tissues from the primary and metastatic tumor 
sites were analyzed separately. In addition, histological 
areas of sarcomatoid or rhabdoid change within the same 
tumor nodule were also analyzed individually. Table 
1 summarizes the clinical-pathological features of the 
selected cases.
Samples’ preparation and NGS sequencing
Pathological slides from all patients and all tumor 
sites have been reviewed blindly by four genito-urinary 
dedicated pathologists (MB, MF, FG and GM) for 
independent assessment of RCC histotype, grading and 
staging, according to the 2016 WHO classification of 
tumours of the urinary system and male genital organs 
[12]. Histological diagnosis was confirmed by routine 
immunohistochemistry in all cases using antibodies anti 
CA-IX and RCC for ccRCC and anti CK7 and Racemase 
for pRCC. Histotype call was performed blindly by at 
least two pathologists with inter-observer variability <5%. 
(data not shown)All the slides of each case have been 
pathologically reviewed and the most representative block 
with highest tumor cell enrichment and highest nucleolar 
grade was selected. Tumor areas of interest with at least 
70% tumor cell enrichment were circled and 10 µm-thick 
serial sections of the same paraffin block cut in sterility for 
DNA extraction. Sections were manually microdissected, 
deparaffinized in xylene and the DNA was isolated 
using the GeneRead DNA FFPE Kit (Qiagen - Hilden, 
Germany). DNA was quantified with the Quantifiler® 
Human DNA Quantification Kit (Thermo Fisher Scientific 
-Waltham, MA). The NGS analysis was performed on an 
Ion PGM™ System (Thermo Fisher Scientific) platform. 
An amplicon library was produced from 10ng of DNA 
from each sample using the Ion AmpliSeq™Cancer 
Hotspot Panel v2 that generates 207 amplicons 
encompassing hotspot and targeted regions of 50 genes 
(ABL1, EGFR, GNAS, KRAS, PTPN11, AKT1, ERBB2, 
GNAQ, MET, RB1, ALK, ERBB4, HNF1A, MLH1, RET, 
APC, EZH2, HRAS, MPL, SMAD4, ATM, FBXW7, IDH1, 
NOTCH1, SMARCB1, BRAF, FGFR1, JAK2, NPM1, 
SMO, CDH1, FGFR2, JAK3, NRAS, SRC, CDKN2A, FG
FR3,IDH2,PDGFRA,STK11,CSF1R,FLT3,KDR,PIK3CA,
TP53,CTNNB1,GNA11,KIT,PTEN,VHL). Amplification of 
target sequences was followed by barcode adapter ligation 
(Ion Xpress Barcode Adapters) to the amplicons that were 
then purified using Agencourt AMPure XP (Beckman 
Coulter - Brea, California). Library quantification was 
performed using the Ion Library TaqMan™ Quantitation 
Kit. The library was diluted in nuclease-free water to 
obtain a final concentration of 8pM. Emulsion PCR was 
performed using Ion PGM™ Template OT2 200 Kit on 
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the Ion OneTouch™ 2 instrument. Library quality was 
assessed using the Qubit Ion Sphere™ Quality Control 
Kit. Selective ion spheres (ISPs) with DNA were isolated 
(Ion PGM™ Enrichment Beads on Ion OneTouch™ ES 
instrument) and sequenced on a Ion 316™ Chip Kit v2 
(5 samples/chip) or a Ion 318™ Chip Kit v2 (10 samples/
chip) using the Ion PGM™ Sequencing 200 Kit v2. 
Successful sequencing of a sample required at least 500 
000 reads with a quality score ≥ Q20. As tumor specimens 
were admixed with normal tissue, a minimum coverage of 
500X with at least 10% frequency was used as cut-off for 
a variant to be considered true.
NGS data analysis
Sequence alignment and base calling were 
performed using the Torrent Suite software v.4.4.3 
(Thermo Fisher Scientific) taking Human Genome Build 
19 (hg19) as the reference. Variant calling was carried 
out with the Variant Caller v.4.4.3.3 plug-in using default 
“Somatic—Low Stringency” settings. Variants were 
further filtered using Ion Reporter software v.4.4 (Thermo 
Fisher Scientific).
The following stringent criteria were applied for 
final variant calling: i) non-synonymous coding; ii) allele 
frequency of ≥10%; iii) total amplicon coverage of ≥500 
reads; iv) a Phred-based quality score of 30 or more and 
P-value <0.01. The Ion Reporter software incorporated 
the following databases: ClinVar, dpSNP (National Center 
for Biotechnology Information, Bethesda, Maryland) and 
COSMIC (Wellcome Trust Sanger Institute, Cambridge, 
United Kingdom) databases. The in-silico prediction tools 
SIFT, PolyPhen, PhyloP and Grantham were also included. 
The Integrative Genomics Viewer (IGV, Broad Institute) 
was used to visualize variants. 
RESULTS
Clinical-pathological data
Seventeen (85%) of the 22 mRCC patients were 
males and five (15%) females. The mean age at diagnosis 
was 57±19. Twenty-one of the 31 RCC samples were 
from the primary tumor site and 11 from metastatic 
lesions. The mean time to the development of metastases 
from the removal of the primary tumor was 13.5 ±14.27 
months (range from 0, synchronous, to 53 months). 
RCC histotypes were distributed as follows: 19 (86%) 
ccRCC and 4 (18%) papillary RCC (pRCC).. One patient 
developed two nodules with ccRCC and pRCC histology 
in the same kidney and the lesions were analyzed 
separately. Metastatic sites included lymph-nodes, 
diaphragm, liver, pancreas, omentum, lung and adrenal. 
Figure 1: A) Low power (2X) of a RCC with B)clear–cell and C) rhabdoid components (20X) and two different 
mutational patterns. D) The rhabdoid component showed the p.V272L hot-spot mutation of the TP53 gene; while E) the clear cell 
counterpart harbored the missense p.Q96FS*63 mutation of the VHL1 gene.
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Table 1: Clinical-pathological patients’characteristics according to mutation variants and line of therapy. 
PR: partial response; PD: progression disease; SD: stable disease.
Table 2: Mutation variants according to gene, tumor site, and rhabdoid or sarcomatoid component. 
Genes Variation Frequency # of patients metastasis kidney sarcomatoid component
rabdhoid 
component histology Response to therapy
VHL
p.S80N (c.239G>A) 10% 1 1 1   ccRCC PR
p.P86T  (c.256C>A) 16,3% 1 1 1   ccRCC PR
p.Q96fs*63 (c.286delC) 23,0% 1  1   ccRCC PD
p.P97R (c.290delCCinsGT) 41,9%-52,6% 1   1 1 ccRCC PD
p.V137fs*7 (c.405_406insT) 41,6%-32,1% 1  1  1 ccRCC PD
p.F91fs*68 (c.271delT) 40,0% 1  1   ccRCC SD
p.W117fs*15 (c.346_347insT) 49,1% 1  1   ccRCC PR
PTEN
1089624295T>TA 11,9% 1 1 1   ccRCC PR
p.L320S (c.959T>C) 43,5%-72,8% 2 1 1   ccRCC/pRCC SD
JAK 3 p.V722I (c.2164G>A) 49,1%-47,3%-51,6% 2 1 1 1 1 ccRCC SD/PD
MET p.R988C (c.2962C>T) 49,4% 1 1 1   ccRCC PR
ERBB4 p.S303Y (c.908C>A) 35,2% 1  1   ccRCC PD
APC p.P1433L (c.4298C>T) 100% 1  1   pRCC PD
CDKN2A p.H83Y (c.247C>T) 10% 1  1   pRCC PD
FGFR3 p.F386L (c.1156T>C) 38,8%-26,9%-48,3% 2 1 2  1 ccRCC PR/PD
EGFR p.G873R (c.2617G>A) 12,40% 1    1 ccRCC SD
RB1 p.I680T (c.2039T>C) 10,50% 1    1 ccRCC SD
TP53
p.V272L (c.814G>T) 17% 1    1 ccRCC PD
p.T172I (c.632C>T) 36,40% 1 1    ccRCC PD
ccRCC: clear cell renal cell carcinoma; pRCC: papillary renal cell carcinoma; PR: partial response; PD: progression disease; SD: stable 
disease
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Both the primary and the metastatic sites were analyzed 
for 6 patients. The rhabdoid and the sarcomatoid tumor 
components were present and have been tested in 4 and in 
1 sample respectively (Table 1).
Mutation variants are different, non-mutually 
exclusive, and variably associated with 
pathological features
The mean read length of the NGS was 105 bp and 
the average reads were approximately 65Mb of sequence 
per sample. With normalization to 2000 reads per 
specimen, 97.08% amplicons averaged at least 500 reads. 
A minimum coverage of 500X with at least 10% frequency 
was used as cutoff for a variant to be considered true. We 
identified mutations in the genes VHL, PTEN, JAK3, MET, 
ERBB4, APC, CDKN2A, FGFR3, EGFR, RB1 and TP53.
Table 1 summarizes the clinical-pathological 
patients’ characteristics according to mutation variants 
and the line of therapy. In particular, the most frequent 
mutations (7/22 patients 31,8%) affected the VHL1 
gene, all were in different loci and except for 3 cases 
were always associated with other mutations. VHL1 was 
mutated in 6 primary RCC, in 2 metastatic sites and in 1 
sarcomatoid and 2 rhabdoid components of primary RCCs. 
The VHL1 mutation variant was concordant between 
primary and the corresponding metastasis in 1 out of 2 
cases. PTEN was found mutated in 3/22 (13,6%) patients 
and only in 1 case was associated with mutations of VHL 
1 and FGFR3. Two cases harbored the same PTEN variant 
(L320S). Two patients (2/22) ( 9%) showed the same 
JAK3 mutation variant (V722I); it was associated with a 
VHL 1 mutation and was revealed both in the sarcomatoid 
and rhadboid component of the same patient, while in the 
other patient it was present as a single mutation in the 
primary RCC and the metastatic lesion. Two patients (9%) 
harboured a mutation of the FGFR3 gene (F386L); in both 
cases it was associated with a VHL1 mutation (1 cases 
also with a PTEN mutation) and each patient presented 
respectively the mutation both in the primary RCC and 
the corresponding metastasis and the clear cell and in the 
rhabdoid component. TP53 was found mutated in 2/22 
(9%) patients:1 in a metastatic lesion and 1 in the rhabdoid 
component of a primary RCC. Mutation in MET gene was 
found in 1/22 patients (4,5%) in the primary RCC and in 
association with VHL1 mutation. ERBB4 mutation were 
discovered in 1/22 (4,5%) patients in both primary and 
metastatic RCC sites, in association with VHL1 mutation. 
Double mutations in the APC and DCKN2A genes was 
found in the same patient in the primary RCC. Mutations 
of EGFR and RB1genes were both detected in 1 patients in 
the rhabdoid component of the primary RCC.
In 9/22 (20%) patients the tumors were wild type 
at least for the investigated genes. There was no relevant 
association between RCC histotype and mutation 
variants. In particular the four pRCC harbored mutations 
in the APC, DCKN2A, PTEN and TP53 genes but not 
in VHL1. Eight (42%) out of the remaining 19 ccRCC 
Table 3: Concordance of mutation variants according to primary/secondary 
tumor site or histological component.
PATIENT Tumor site/component GENE/MUTATION/VARIANTS
1
kidney FGFR3 VHL1 PTEN 
diaphragm FGFR3 VHL1 PTEN 
2
kidney VHL1 MET  
lung VHL1 MET  
3
adrenal gland    
kidney    
6
kidney    
pancreas    
7
kidney JAK3   
lung JAK3   
13
kidney (rhadboid) EGFR RB1  
liver PTEN   
15
kidney (rhadboid) TP53   
kidney VHL1   
16
kidney    
kidney PTEN   
17
kidney (rhadboid) FGFR3 VHL1  
kidney FGFR3 VHL1  
18
kidney (sarcomatoid) VHL1 JAK3  
kidney (rhadboid) VHL1 JAK3  
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tumors habored at least one VHL1 mutation although with 
different variants.
As depicted in Table 3, the concordance between 
the primary RCC and its rhadboid/sarcomatoid component 
was seen in 2/3 cases: FGFR3 F386L and VHL1 V13fs*7 
(rhabdoid and primary RCC) and VHL1 P97R and JAK3 
(rhabdoid and sarcomatoid component of RCC). In the 
remaining case the gene mutations between the RCC and 
its rhabdoid component were completely different. The 
concordance between RCC and its metastatic lesion was 
found in 3/6 cases while in the remaining case the genetic 
alterations were different. 
Response to target therapy is irrespective of 
mutation variants
Table 1 depicts response to therapy for each patient 
while Table 2 summarizes the mutation variants found by 
gene, tumor site, and rhabdoid or sarcomatoid component.
Six (27%) mRCC patients underwent first-line 
therapy with Sorafenib, 15 (68%) with Sunitinib and 1 
(4%) with Temsirolimus. Radiological partial response 
(PR) was obtained in 4 (18,2%) patients after at least one 
cycle of first-line therapy with TKI (2 after Sunitinib and 
2 Sorafenib). Disease stabilization (SD) as best response 
was reached in 7 (31,8%) patients (6 after Sunitinib and 
1 after Sorafenib), while the remaining 11 (50%) patients 
experienced early disease progression (7 after Sunitinib, 3 
after Sorafenib and 1 after Temsirolimus). 
Among the 4 partial responders, 1 (25%) was wild-
type for all genes and 3 (75%) harbored different VHL1 
variants. Among the 7 patients with disease stabilization 
2 (29%) were wild-type for all genes, 2 (29%)were PTEN 
mutated, and mutations in single patients (14% each) were 
found for VHL1, JAK3 and APC/CDKN2A. Twelve (55%) 
patients underwent second-line therapy after progression 
to first-line agents: 4 (18%) with Sorafenib, 1 (4%) with 
Sunitinib and 7 (32%) with Everolimus. None of these 
patients showed partial response after second-line therapy 
with just one case of disease stabilization after Axitinib. 
Among the 11 non-responders 7 (64%) were 
wild-type for all genes, 2 (18%) were TP53 mutated (in 
different loci) and 2 (18%) were VHL1 mutated.
The mean follow-up time was 27,5 months (range 
6-78). Four of the 22 (18,2%) patients were alive at the 
time of last follow-up and only 1 was lost from follow up 
after 30 months. Of these 5 long survivors 4 (80%) were 
treated with Sunitinib and 1 (20%) with Sorafenib. Two 
patients harbouring just the same PTEN L320S mutation 
survived for at least 27 or 30 months.
DISCUSSION
Renal cell cancer is as an heterogenous disease 
based on its morphological and molecular features. 
The ccRCC is largely the most common histotype and 
it is tightly associated with alteration of the VHL1-HIF 
pathway, while non-clear cell tumors are characterized 
by alterations of the PI3K and MET pathways. However, 
a large morphological and molecular inter-tumor 
heterogeneity may occur within the same histotype and 
intra-tumor in primary and metastatic lesions of the same 
patient. [4] 
Here we provided one of the few available reports 
on wide spectrum mutation analysis on mRCC on an 
NGS platform. Although we did not find a significant 
association between histotype and mutation variants 
we found that approximately 40% of ccRCC harboured 
mutations of VHL1 gene compared to none in the pRCC 
group. We found a large number of mutations in different 
genes. Mutations in some genes such as VHL1, PTEN, 
JAK3 and TP53 are well recognized. [13, 14, 15] By 
contrast, mutations in the genes APC, ERBB4, RB1, 
EGFR, FGFR3 have been rarely or never found in RCC 
but were encountered in our series. [16] As far as we 
can say from our data these mutations are non-mutually 
exclusive and hit a variable number of loci. In addition, 
we did not find any significant correlation between 
sarcomatoid or rhabdoid RCC features and specific gene 
alterations while concordance between primary RCC and 
the corresponding metastasis was found in three of six 
cases. Taken together all these data bring to the conclusion 
that more gene variants than expected are associated with 
mRCC, and are non-mutually exclusive. Mutations of 
VHL1 are the most frequent but involve wide number of 
loci.
Major limitations affect the present study. The 
limited number of cases and the even smaller number of 
patients with available primary tumors and metastases 
do not allow drawing definitive conclusions on the intra-
tumor heterogeneity in terms of both mixed histotypes or 
primary/metastases variability. In addition, our mutational 
analysis is based on a panel generating 207 amplicons 
covering approximately 2,800 COSMIC mutations from 
50 of the most altered oncogenes and tumor suppressor 
genes in solid tumors. We may have missed mutations in 
the genes outside the list of our panel as well as genetic 
rearrangements detectable just at the RNA level. Larger 
studies covering all the RCC histotypes with paired 
samples of primary tumors and metastases are required to 
answer the intra-tumor heterogeneity question. 
Since 70 to 80% of patients obtain a benefit from 
a first line therapy, a large (and presently increasing) 
number of mRCC patients are treated sequentially with 
different agents. [17] Unfortunately, there are no current 
validated predictive biomarkers of response to these target 
therapies. Our retrospective analysis confirmed that there 
are no single predictors of response to therapy with TKIs 
or mTOR inhibitors. In fact, we found that three of the 
four patients experiencing partial response after first-line 
therapy were treated with a TKI with anti-angiogenetic 
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activity and actually harbored mutations of the pro-
angiogenic gene VHL1, although in different loci. By 
contrast, other three patients with tumors harboring VHL1 
mutations experienced progressive disease with similar 
therapies. Although in few patients, this finding is in line 
with other studies reporting no association between VHL1 
mutations and objective responses to anti-angiogenic 
TKIs. [18, 19] Interestingly, seven (64%) of the 11 
mRCC patients who did not respond even at the first-line 
treatment were completely wild-type at least for the 50 
genes included in our panel. Although we have no helpful 
explanation for this lack of response we can hypothesize 
that the absence of target mutations may have decreased 
the therapeutic effectiveness of the multi TKI agents. This 
phenomenon is for instance well known in the subset of 
gastro-intestinal stromal tumors that are wild-type for the 
KIT and PDGFRA genes and generally do not respond to 
TKIs such as Imatinib and Sunitinib. [20] Another possible 
explanation is that other genetic alterations, not included 
in our mutational panel, may confer resistance to TKIs or 
mTOR inhibitors. 
It is also noteworthy that our data do not seem 
to confirm the well known role of mutations within the 
mTOR patway components to predict long term benefit 
from mTOR inhibitors. [21, 22] This discrepancy could 
be explained with the little number of cases treated 
with Temsirolimus as first-line therapy in our series. 
An interesting aspect of our work is the finding of rare 
potentially actionable mutations such as FGFR3 and 
JAK3 for which effective targeted agents are available and 
currently under investigation in other tumor types
We can therefore conclude that in the absence of 
established molecular predictors of response to targeted 
therapies in mRCC an NGS approach may address single 
patients to basket trials enrolling according to molecular 
specific alterations regardless of the pathological features. 
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